Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. August 2026 16:15 ET | Quelle: CRISPR Therapeutics AG

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second...
03. August 2026 16:01 ET | Quelle: Damora Therapeutics, Inc.

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today...
03. August 2026 08:30 ET | Quelle: Cue Biopharma, Inc.

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today...
03. August 2026 08:05 ET | Quelle: Candel Therapeutics

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
03. August 2026 07:38 ET | Quelle: Curium

Curium Announces Definitive Agreement to Merge with Lantheus

$8B Curium-Lantheus deal creates a global radiopharmaceutical leader, expanding reach across oncology, neurology and cardiology in 70+ countries.
03. August 2026 07:31 ET | Quelle: Lantheus Holdings, Inc.

Curium Announces Definitive Agreement to Merge with Lantheus

Strategic transaction would bring Curium's theranostics portfolio and global manufacturing platform together with Lantheus’ complementary U.S. radiodiagnostics business Total transaction...
03. August 2026 07:30 ET | Quelle: Zevra Therapeutics

Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people...
31. Juli 2026 16:01 ET | Quelle: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, BC and BOSTON, MA, July 31, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...
30. Juli 2026 16:01 ET | Quelle: Xenon Pharmaceuticals Inc.

Xenon to Report Q2 2026 Financial Results on August 6, 2026

VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical...
30. Juli 2026 13:00 ET | Quelle: DelveInsight Business Research LLP

Peripheral Artery Disease Clinical Trial Pipeline Expands as 17+ Companies Race to Redefine Peripheral Artery Disease Treatment Landscape | DelveInsight

New York, USA, July 30, 2026 (GLOBE NEWSWIRE) -- Peripheral Artery Disease Clinical Trial Pipeline Expands as 17+ Companies Race to Redefine Peripheral Artery Disease Treatment Landscape |...

Nächste Seite